CN1478497A

CN1478497A - Medicine for treating fatty liver

Info

Publication number: CN1478497A
Application number: CNA021328587A
Authority: CN
Inventors: 邱学良
Original assignee: Individual
Current assignee: Individual
Priority date: 2002-08-31
Filing date: 2002-08-31
Publication date: 2004-03-03
Anticipated expiration: 2022-08-31
Also published as: CN1229124C

Abstract

A Chinese medicine for treating fatty liver is prepared from 4 Chinese-medicinal materials: alismatic rhizome, red sage root, turmeric and rhubarb. Its advantage is high curative effect.

Description

The medicine of treatment fatty liver

Technical field: the present invention relates to a kind of Chinese patent medicine for the treatment of fatty liver.

Background technology: fatty liver is a kind of clinical picture that multiple reason causes.I in recent years incidence rate the trend that day by day increases is arranged, show that according to interrelated data fatty liver adult prevalence is at 5%-9%.The reason that causes fatty liver is a lot, and as nutritional disorder, heavy drinking, diabetes, infection, medicine damage, metabolism and dyshormonia etc., in many steatosis, ethanol is first of the cause of disease, accounts for 40%-45%.

A large amount of fat are piled up in hepatocyte, often make liver function damage, even cause hepatic fibrosis, and liver cirrhosis finally takes place, and cause adverse consequences.Modern medicine is mainly etiological treatment to the treatment of fatty liver, cause that by releasing the different causes of disease that fatty liver takes place make it obtain taking a turn for the better or recovering, also use the medicine that promotes that liver is eliminated excess fat or stoped fat to store in liver, but curative effect depends on the type of fatty liver.

Clinical this sick medicine that is used for the treatment of there is no sure curative effect at present, it mainly is the desired substance that replenishes in the hepatocyte metabolic process, the liver cirrhosis that occurs for the fatty liver later stage more lacks effective medicine, though the medicine of existing some fibrosis comes out at present, and further checking that need be clinical

Chinese medicine thinks that the main etiology and pathogenesis of primary disease is an eating and drinking without temperance, and surfeit rich and fatty diet or heavy drinking make damp and hot interior giving birth to, or the wet expectorant that gathers into, cause damp-heat gluing each other, the retardance meridians make the stagnation of QI not all right, blood stasis resistance network, water-damp retention, thus a series of corresponding syndromes take place.

Summary of the invention: the purpose of this invention is to provide a kind of the have hepatocyte of alleviating harm and dysbolismus, prevention steatosis, have the medicine of lipotropy.

Above-mentioned purpose realizes by following technical scheme:

The medicine of treatment fatty liver, it is the medicament of being made by the Chinese medicine of following weight proportioning:

Rhizoma Alismatis 20～80 Radix Salviae Miltiorrhizaes 10～40

Rhizoma Curcumae Longae 10～40 Radix Et Rhizoma Rhei 2～8.

The medicine of above-mentioned treatment fatty liver, wherein the weight proportion of Chinese medicine is:

Rhizoma Alismatis 50 Radix Salviae Miltiorrhizaes 25

Rhizoma Curcumae Longae 25 Radix Et Rhizoma Rhei 5.

This technical scheme has following beneficial effect:

One, solution of the present invention is based on understanding and the Therapeutic Principle of motherland's traditional medicine to hepatopathy, with reference to the modern pharmacological research achievement, from motherland medicine treasure-house, filter out have blood fat reducing, the reparation and the regenerated natural plant of anti-fatty liver, promotion tissue, press the Chinese medical theory prescription, science skims the cream off milk, make evident in efficacy, the medicine of taking convenience.Prove that through pharmacological evaluation this product has the function that protects the liver, can play the effect of treatment chronic active, chronic persistent hepatitis B.

Use this product, drug withdrawal does not rebound, and price is low.With the purine nucleosides antiviral drugs fashionable for a time eighties, other antiviral agent such as ribavirin, suramin, the third chlorine guanosine etc. are compared, and toxicity is low, examines sweet class preparation such as lamivudine etc. with a new generation and compares short treating period, stable curative effect.This product can fundamentally suppress, remove hepatitis B virus.Has the function of eliminating hepatitis B virus, the liver protecting, enhancing human body immunity power, preventing hepatic fibrosis.

Two, the prescription uniqueness of medicine of the present invention, be to adopt Rhizoma Alismatis and protect the liver and promote tissue repair, regenerated salviamiltiorrhizabung to carry out compatibility with anti-fatty liver, effect for reducing blood fat, to reduce the lipid content of fatty live lesions, hepatic injury is recovered, and the formation of promotion liver collateral circulation, help hepatocellular recovery and regeneration; And add the drug for invigorating blood circulation and eliminating stasis Rhizoma Curcumae Longae, with the promotion bile secretion, and blood fat reducing, alleviate atheromatous plaque.In compatibility, added Radix Et Rhizoma Rhei, made this product have the gallbladder of promotion and shrink and the cholesterol reducing effect, promoted the effect of above medicine performance depressed liver-energy dispersing and function of gallbladder promoting, thereby fundamentally eliminate the pathogenesis of fatty liver factor.Zoopery proves that medicine of the present invention has the effect of tangible anti-fatty liver, blood fat reducing.

Three, drug toxicology of the present invention and pharmacodynamics test show safety non-toxic, and fatty liver is had certain curative effect.Testing data is as follows:

1, with the maximum stomach concentration of irritating of medicine of the present invention, the mouse stomach maximum volume is administered three times to mouse stomach,, each 0.4g/20g, each 4 hours blanking times, administration one day was observed 7 days continuously, did not see dead and obviously unusual performance.Recording maximum tolerated dose is 60g/kg, is equivalent to 625 times of clinical consumptions, and the consumption per day that shows medicine of the present invention is safe.

2, long term toxicity test: give the Wistar rat oral gavage with 4g/kg, 2g/kg, 1g/kg dosage respectively, the administration volume is the 2ml/100g body weight, and matched group is given and normal saline with volume, irritates stomach every day once, successive administration 3 months.The result shows that large, medium and small three dosage of the long poison experiment of medicine of the present invention all do not have obvious influence to body weight, routine blood test, hepatic and renal function, the organ index of rat.

3, (1) is to the effect for reducing fat of egg-nog hyperlipemia disease mice: 50 of mices, be divided into normal control, model group, JIANGZHILINGPIAN 0.4g/kg group, medicine 0.3 at random, 0.6g/kg group, test group and model group be gastric infusion respectively, leave standstill 5h, ip75% egg-nog 20ml/kg, fasting 10h, test group and model group are administered once again, the normal control group is only given distilled water 20ml/kg, and last administration 2h gets blood by the right eye venous plexus, 3000r/min * 10min centrifugalize serum, then serum TC H, TC and HDL value are as table 1.

(2) to the effect for reducing blood fat of Triton-WR1339 hyperlipemia in mice: 20 ~ 22g mice, the male and female dual-purpose, divide normal control group, model group, JIANGZHILINGPIAN 0.4g/kg and medicine 0.3 at random, 0.6g/kg 5 groups of fasting 4h, normal control and model group all give distilled water 20ml/kg, drug component does not give the drug suspension 20ml/kg of variable concentrations, dosage is: JIANGZHILINGPIAN 0.4g/kg, medicine 0.3,0.6g/kg administration 4h, except that the normal control group, equal ipTriton-WR1339 400mg/kg is in 2 and 10h administration 2 times more respectively.Behind the mice last administration 4h, get blood 3000r/min * 10min.

Pharmacodynamic test of active extract shows: medicine of the present invention has tangible anti-HBV effect; can resist antigen of hepatitis B virus, reduce hepatitis B duck model serum transaminase; to anti-liver injury, the liver protecting effect; and immunologic function had stronger facilitation; not only can improve non-specific immunity, and also have certain facilitation for the humoral immunization and the cellular immunization of specific immunity.

Embodiment 1:

Rhizoma Alismatis 20,30,40,50,60,70 or 80

Radix Salviae Miltiorrhizae 10,20,30 or 40

Rhizoma Curcumae Longae 10,20,30 or 40

Radix Et Rhizoma Rhei 2,4,6 or 8.

Concrete above-mentioned each component made medicine production method of the present invention be:

1. three flavors such as Rhizoma Alismatis, Radix Salviae Miltiorrhizae, Rhizoma Curcumae Longae add 75% alcohol reflux, and medicinal residues discard, and extracting solution reclaims ethanol to the clear paste shape.

2. Radix Et Rhizoma Rhei decocts with water 2 times, discards medicinal residues, and filtrate is concentrated into the clear paste of relative density 1.20～1.24 (80 ℃), adds ethanol and reaches 65% to containing the alcohol amount, filters, and filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.32 ~ 1.34 (80 ℃).

3. with above-mentioned two kinds of clear paste mixings, add adjuvant, adopt one-step-granulating method to granulate, make 1000 tablet or granule, capsule.

Embodiment 2:

The preparation method of the medicine of above-mentioned treatment fatty liver: take by weighing raw material (gram) by following proportioning, effect is preferable:

Rhizoma Alismatis 50 Radix Salviae Miltiorrhizaes 25

Rhizoma Curcumae Longae 25 Radix Et Rhizoma Rhei 5.

Three flavors such as Rhizoma Alismatis, Radix Salviae Miltiorrhizae, Rhizoma Curcumae Longae are added 75% alcohol reflux, and medicinal residues discard, and extracting solution reclaims ethanol to the clear paste shape.Radix Et Rhizoma Rhei decocts with water 2 times, discards medicinal residues, and filtrate is concentrated into the clear paste of relative density 1.20～1.24 (80 ℃), adds ethanol and reaches 65% to containing the alcohol amount, filters, and filtrate recycling ethanol also is concentrated into the clear paste that relative density is 1.32 ~ 1.34 (80 ℃).With above-mentioned two kinds of clear paste mixings, add adjuvant, adopt one-step-granulating method to granulate, make 1000 tablet or granule, capsule.

Also can make said dosage form on any pharmaceutics.Comprise: tablet, capsule, granule, oral liquid.

Usage and consumption: oral, a 2-4 sheet, 3 times on the one.

Claims

1. medicine for the treatment of fatty liver, it is characterized in that: it is the medicament of being made by the Chinese medicine of following weight proportioning:

Rhizoma Alismatis 20～80 Radix Salviae Miltiorrhizaes 10～40

Rhizoma Curcumae Longae 10～40 Radix Et Rhizoma Rhei 2～8.

2. the medicine of treatment fatty liver according to claim 1 is characterized in that: wherein the weight proportion of Chinese medicine is:

Rhizoma Alismatis 50 Radix Salviae Miltiorrhizaes 25

Rhizoma Curcumae Longae 25 Radix Et Rhizoma Rhei 5

3. according to the medicine of claim 1,2 described treatment fatty livers, it is characterized in that said medicament is a said dosage form on any pharmaceutics.

4. the medicine of treatment fatty liver according to claim 3 is characterized in that said medicament is tablet, capsule, granule, oral liquid.